TY - JOUR T1 - Non-alcoholic fatty liver disease (NAFLD) prevalence in Latin American and the Caribbean: Protocol for a systematic review JF - medRxiv DO - 10.1101/2020.11.16.20232744 SP - 2020.11.16.20232744 AU - Yesmi Arcelia Ortega Rojas AU - Claudia Lucía Vidal Cuéllar AU - Karina Mercedes Aparicio Barrón AU - Rodrigo Carrillo Larco Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/18/2020.11.16.20232744.abstract N2 - Background Non-alcoholic fatty liver disease (NAFLD) is the most common worldwide cause of chronic liver disease and it carries a significant economic burden for the healthcare system. The worldwide prevalence of NAFLD appears to be 25%, with the highest rates in Latin America and the Caribbean (LAC) and the middle west. Prevalence of NAFLD in LAC has not been well represented in multiple global meta-analyses because they did not include regional search engines or excluded papers in Spanish. Furthermore, older estimates may not represent the current epidemiological situation given the recent rise of several risk factors like obesity, unhealthy diet and lifestyles in LAC.Objective To estimate the prevalence of NAFLD in the general adult population of LAC.Methods Systematic review and meta-analysis. We will conduct a search in OVID (MEDLINE, Embase, Global Health), Cochrane Library, and LILACS. Search terms include those related to non-alcoholic fatty liver disease, along with countries in LAC. We seek observational studies with a random sample of the general population, closed populations, and patients; results will be presented for each of these groups. Titles and abstracts will be screened by two reviewers independently. After the screening phase, we will download the full-text of the selected publications and two reviewers will comprehensively read these papers. If there is any discrepancy in any of these two selection phases, it will be solved by consensus by the two reviewers or by a third party. An extraction data form in a spreadsheet will be developed and tested with a random sample of five selected studies. The data extracted will include study details, sample size, method of NAFLD diagnosis and prevalence of NAFLD. Data extraction will be conducted by two reviewers independently. We will use the risk of bias tool proposed by Hoy and colleagues. We will report the main features of the selected reports in tables, this will include the prevalence estimates. We will pool the prevalence estimates. We will only conduct the meta-analysis if there are three or more individual estimates and there is not large heterogeneity amongst them. We will conduct all statistical analyses using Stata 16.0Conclusions This systematic review and meta-analysis will provide updated evidence about the prevalence of NAFLD in LAC. Thereby, we will increase NAFLD awareness as a public health problem in LAC, and our results can inform strategies and interventions to reduce NAFLD burden in LAC. We will also pinpoint research needs and discuss future steps so that more robust evidence about NAFLD becomes available in LAC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRodrigo M Carrillo-Larco is supported by a Wellcome Trust International Training Fellowship (214185/Z/18/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review protocol. No human subjects were involved in this project. Thus, this study was classified as non-human subject research. Therefore, no approval was needed from an IRB/ethics committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a systematic review protocol, and no data have been analysed. ER -